Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0955-3886(95)97393-e | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transfusion-associated graft-versus-host disease (TA-GVHD) and graft-versus-host disease (GVHD): Pathophysiology and management (contrasted and compared).
Hematol Oncol Stem Cell Ther
January 2025
Hematology Laboratory-Blood Bank, Aretaieion Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Transfusion of blood products is a common lifesaving medical procedure in clinical practice. However, it poses the risk of potential adverse reactions for the recipient. Transfusion-associated graft-versus-host-disease (TA-GVHD) is a rare adverse event, fatal in >90% of cases.
View Article and Find Full Text PDFCombined Solid Organ Transplant and Transfusion-Associated Graft-Versus-Host Disease in a Lung Transplant Recipient: An Uncertain Culprit With Lethal Complications.
Case Rep Transplant
December 2024
Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona, USA.
Although graft-versus-host disease (GVHD) is a common complication of hematopoietic stem cell transplantation, it is rare after solid organ transplantation (SOT) or blood transfusion. We present a rare case of SOT-derived and/or transfusion-associated graft-versus-host disease (TA-GVHD) in a 66-year-old man with interstitial lung disease who underwent bilateral lung transplantation (LT) from a 12-year-old female donor and required three units of packed red blood cells intraoperatively. He presented with signs and symptoms consistent with GVHD, and a bone marrow biopsy revealed an XX karyotype.
View Article and Find Full Text PDFEffect of concurrent pathogen reduction (amotosalen/UVA) and gamma/x-ray irradiation on biochemical characteristics of apheresis platelets in additive solution.
Transfusion
January 2025
Laboratory of Cellular Hematology, DBCD, OBRR, CBER, FDA, Silver Spring, Maryland, USA.
Background: Pathogen reduction (PR) may be used as an alternative to gamma or x-ray irradiation (I) to prevent transfusion associated graft versus host disease (TA-GVHD) if the pathogen reduction technology has been shown to inactivate residual lymphocytes. However, as I is considered the gold standard for reducing the risk of TA-GVHD, some centers continue to perform I in addition to PR. This study investigated the effect of concurrent pathogen reduction and irradiation (PR/I) on the biochemical characteristics of apheresis platelets at day 1, 5, and 7 of storage at room temperature.
View Article and Find Full Text PDFTransfusion-Associated Graft-Versus-Host Disease in Pediatric Patients: Clinical Features and Outcomes.
Pediatr Dermatol
November 2024
Dermatology Department, Instituto Nacional de Pediatría, Mexico City, Mexico.
Background: Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare, usually fatal complication of blood transfusion.
Objective: To describe the characteristics of TA-GVHD in children.
Methods: The clinical records of pediatric patients diagnosed with TA-GVHD between January 2007 and December 2021 were reviewed.
Transfusion-associated graft-versus-host disease in an immunocompetent individual.
BMJ Case Rep
October 2024
Internal Medicine, The Aga Khan University, Karachi, Sindh, Pakistan.
Transfusion-associated graft-versus-host disease (TA-GVHD) is a fatal complication that occurs in both immunocompromised and immunocompetent individuals following blood transfusion. It is characterised by donor lymphocyte attacks on recipient tissues. We present a case of TA-GVHD in an immunocompetent man in his 70s who developed fever, diarrhoea, rash and pancytopenia after non-irradiated blood transfusion from an unrelated donor.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!